Wells Fargo Maintains Overweight on Abbott Laboratories, Lowers Price Target to $116
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Lawrence Biegelsen has maintained an Overweight rating on Abbott Laboratories (NYSE:ABT) but lowered the price target from $136 to $116.
October 19, 2023 | 1:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Abbott Laboratories' price target has been lowered from $136 to $116 by Wells Fargo, though the Overweight rating is maintained.
The lowering of the price target by Wells Fargo indicates a potential decrease in the short-term value of Abbott Laboratories' stock. However, the maintained Overweight rating suggests that the stock is still expected to outperform.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100